

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1647
Jacques BOLLEKENS, et al. Examiner: SAOUD, CHRISTINE J.
INTERNATIONAL APPLICATION NO: PCT/EP2004/012572
FILED: 5 November 2004
U.S. APPLICATION NO.: 10/578,470
FILED: 18 April 2008
FOR: Use of Fibroblast Growth Factor Fragments

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

This is in response to the Final Office Action mailed on 4 February 2011, a response to which is due 4 May 2011. A Request for Continued Examination (RCE) is filed herewith.

The Commissioner is hereby authorized to charge the RCE fee and any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 50-4409 in the name of Novartis.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the Listing of the Claims which begins on page 4 of this paper.

Arguments/Remarks begin on page 8 of this paper.